Literature DB >> 28007600

Sox9 mediated transcriptional activation of FOXK2 is critical for colorectal cancer cells proliferation.

Yu Qian1, Suhua Xia2, Zhenyu Feng3.   

Abstract

FOXK2, which belongs to the fork head DNA binding protein family, has been shown to play a critical role in tumorigenesis. Here, we detected FOXK2 expression and its clinical significance in colorectal cancer, which has not been fully investigated before. Results from public database and our cohort indicated that FOXK2 was transcriptionally activated in colorectal cancer tissues compared to non-cancer tissues. High expression of FOXK2 was significantly correlated with poor survival. In vitro cell experiments suggested that FOXK2 promoted cell proliferation. Furthermore, we found that oncogene SOX9 was responsible for the up-regulation of FOXK2 by directly binding on its promoter. Depletion of FOXK2 attenuated SOX9 induced cell growth. In addition, we observed that the expression of FOXK2 was significantly associated with the expression of SOX9 both in the public database and our colorectal cancer tissues. The patients with SOX9+FOXK2+ had a poor overall survival (p = 0.0084). In conclusion, our data suggested that SOX9 transcriptionally activated FOXK2 was involved in the pathogenesis of colorectal cancer and might be a novel target for colorectal cancer therapy.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; FOXK2; SOX9

Mesh:

Substances:

Year:  2016        PMID: 28007600     DOI: 10.1016/j.bbrc.2016.12.119

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

1.  Prognostic Value of the FOXK Family Expression in Patients with Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiotherapy.

Authors:  Yiyi Zhang; Meifang Xu; Jianhua Chen; Kui Chen; Jinfu Zhuang; Yuanfeng Yang; Xing Liu; Guoxian Guan
Journal:  Onco Targets Ther       Date:  2020-09-16       Impact factor: 4.147

2.  Forkhead box K2 inhibits the proliferation, migration, and invasion of human glioma cells and predicts a favorable prognosis.

Authors:  Bo Wang; XueBin Zhang; Wei Wang; ZhiZhong Zhu; Fan Tang; Dong Wang; Xi Liu; Hao Zhuang; XiaoLing Yan
Journal:  Onco Targets Ther       Date:  2018-02-27       Impact factor: 4.147

3.  Pyrroline-5-carboxylate reductase 1 promotes cell proliferation via inhibiting apoptosis in human malignant melanoma.

Authors:  Yingyi Ye; Yingying Wu; Jinyan Wang
Journal:  Cancer Manag Res       Date:  2018-11-27       Impact factor: 3.989

Review 4.  The forkhead-box family of transcription factors: key molecular players in colorectal cancer pathogenesis.

Authors:  Paul Laissue
Journal:  Mol Cancer       Date:  2019-01-08       Impact factor: 27.401

5.  Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR.

Authors:  Feng Du; Chenyang Qiao; Xiaowei Li; Zhangqian Chen; Hao Liu; Shengda Wu; Sijun Hu; Zhaoyan Qiu; Meirui Qian; Dean Tian; Kaichun Wu; Daiming Fan; Yongzhan Nie; Limin Xia
Journal:  Theranostics       Date:  2019-05-31       Impact factor: 11.556

6.  Upregulated SOX9 expression indicates worse prognosis in solid tumors: a systematic review and meta-analysis.

Authors:  Haihua Ruan; Shuangyan Hu; Hongyu Zhang; Gang Du; Xiaoting Li; Xiaobo Li; Xichuan Li
Journal:  Oncotarget       Date:  2017-11-06

7.  The effects of lncRNA MALAT1 on proliferation, invasion and migration in colorectal cancer through regulating SOX9.

Authors:  Yuanlin Xu; Xihong Zhang; Xiufeng Hu; Wenping Zhou; Peipei Zhang; Jiuyang Zhang; Shujun Yang; Yanyan Liu
Journal:  Mol Med       Date:  2018-10-03       Impact factor: 6.354

8.  Downregulation of FOXK2 is associated with poor prognosis in patients with gastric cancer.

Authors:  Xi Liu; Xiaodong Wei; Wei Niu; Dong Wang; Bo Wang; Hao Zhuang
Journal:  Mol Med Rep       Date:  2018-09-07       Impact factor: 2.952

Review 9.  SOX9 Stem-Cell Factor: Clinical and Functional Relevance in Cancer.

Authors:  Maribel Aguilar-Medina; Mariana Avendaño-Félix; Erik Lizárraga-Verdugo; Mercedes Bermúdez; José Geovanni Romero-Quintana; Rosalío Ramos-Payan; Erika Ruíz-García; César López-Camarillo
Journal:  J Oncol       Date:  2019-04-01       Impact factor: 4.375

10.  Overexpression of GPR35 confers drug resistance in NSCLC cells by β-arrestin/Akt signaling.

Authors:  Wei Wang; Tianci Han; Wei Tong; Jian Zhao; Xueshan Qiu
Journal:  Onco Targets Ther       Date:  2018-09-26       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.